Appointed
Jay Kranzler
Chairman of the Board
ATXI ·
AVENUE THERAPEUTICS, INC.
appointed Jay Kranzler, M.D., Ph.D. to serve as Chairman of the Board, effective immediately
Ready 8-Ks
50
Latest filing
February 23, 2026, 6:59 PM ET
Top materiality
0.90
Event mix
other_material ×18 · regulatory ×13 · earnings ×9
Sentiment
7 pos · 13 neg · 30 neu
Latest earnings
reported 2023-Q3
Executive change
recent →
Recent 8-K filings for ATXI
Highest-materiality recent filing
Nasdaq to delist Avenue Therapeutics on March 19; stock to trade on OTC Markets
- Nasdaq notified Company it will delist common stock effective at open on March 19, 2025.
- Delisting due to failure to maintain minimum $2.5M stockholders' equity per Nasdaq Rule 5550(b)(1).
-
Exclusive worldwide license from Duke for ATX-04 (clenbuterol) to treat Pompe disease as adjunct to ERT.
-
Axsome acquires 100% of Baergic Bio equity for $0.3M upfront; development/regulatory milestones up to $2.5M (first indication) and $1.5M per subsequent indication.
-
Avenue Therapeutics terminates AJ201 license; gets $2M cash, up to $24M milestones, 1.75% royalty
License terminated; all AJ201 rights and assets transferred back to AnnJi; mutual releases and dismissal of disputes.
-
Nasdaq to delist Avenue Therapeutics on March 19; stock to trade on OTC Markets
Nasdaq notified Company it will delist common stock effective at open on March 19, 2025.
-
Nasdaq Panel granted continued listing subject to: public disclosure by Mar 14, fundraising update by Mar 14, AJ201 trial results by Apr 15.
-
Stockholders' equity of $1.652M as of Sep 30, 2024, below Nasdaq's $2.5M minimum requirement.
-
Avenue Therapeutics Q3 2024 net loss $3.1M; cash $2.6M; AJ201 data expected year-end
Net loss of $3.1M ($1.92/share) vs net income of $0.5M in Q3 2023.
-
Avenue Therapeutics Q2 2024 net loss $2.7M; AJ201 trial topline data expected H2 2024
Cash and equivalents $4.9M at June 30, 2024, up from $1.8M at Dec 31, 2023.
-
Notified by Nasdaq on May 21, 2024, that it meets minimum stockholders' equity requirement for continued listing.
-
Net loss $4.3M ($15.40/share) vs $7.5M ($101.57) in Q1 2023; R&D $2.4M, G&A $1.3M.
-
Avenue Therapeutics enters $3.85M ATM equity offering agreement with H.C. Wainwright
Company entered ATM offering agreement with H.C. Wainwright for up to $3,850,000 in common stock sales.
-
Avenue Therapeutics raises $4.4M via warrant exercise inducement; issues new warrants
Holders exercised 689,680 existing warrants at reduced price of $6.20/share for $4.4M gross proceeds.
-
Avenue Therapeutics effects 1-for-75 reverse stock split to meet Nasdaq bid price rule
Reverse split effective April 26, 2024; shares reduced from ~44.7M to ~0.6M.
-
Nasdaq issues delist determination for Avenue Therapeutics; extension to May 20 granted
Nasdaq Staff issued delist determination on March 26, 2024 for failing Bid Price Rule ($1.00 minimum).
-
Net loss of $10.5M ($0.98 per share) vs $3.6M loss in FY2022; cash $1.8M as of Dec 31, 2023.
-
Nasdaq panel grants Avenue Therapeutics extension to May 20, 2024 for listing compliance
Nasdaq Hearings Panel granted extension through May 20, 2024 to meet stockholders' equity and bid price requirements.
-
Avenue Therapeutics stockholders approve reverse stock split in range 30:1 to 75:1
Majority of voting power executed written consent on March 6, 2024, approving reverse stock split.
-
Gross proceeds ~$5.0M from immediate cash exercise of 16.5M existing warrants at reduced exercise price of $0.3006/share.
-
Avenue Therapeutics receives Nasdaq delisting notice for continued non-compliance with equity rule
Failed to meet Nasdaq's $2.5M stockholders' equity requirement by Nov 15, 2023 extension deadline.
-
Avenue Therapeutics reports Q3 net income of $0.5M; cash low, raises $5M
Net income $0.5M ($0.06 per share) vs net loss $0.7M in Q3 2022; R&D $0.9M, G&A $1.2M.
-
Avenue Therapeutics closes $5M public offering of stock and warrants
Gross proceeds ~$5.0M; estimated net proceeds ~$4.1M after placement agent fees and expenses.
-
Received Nasdaq notice on Sept 27, 2023 for non-compliance with minimum bid price requirement (Rule 5550(a)(2)).
-
Net loss of $4.0M ($0.52 per share) vs $0.6M ($0.41) in Q2 2022; cash $1.6M down from $6.7M at year-end 2022.
-
Avenue Therapeutics receives Nasdaq deficiency notice for negative stockholders' equity
Nasdaq notified Avenue Therapeutics on May 19, 2023, of non-compliance with minimum $2.5M stockholders' equity requirement.
-
Avenue Therapeutics Q1 net loss $7.5M; advances AJ201 and IV Tramadol programs
Net loss of $7.5M ($1.37 per share) vs $2.9M loss ($2.05 per share) in Q1 2022.
-
Avenue Therapeutics announces FDA agreement on most protocol items for IV Tramadol safety study
Received official meeting minutes from FDA Type C meeting on March 9, 2023, for IV Tramadol.
-
Avenue Therapeutics licenses AJ201 from AnnJi for SBMA; upfront $3M cash + stock
Upfront cash license fee of $3M ($2M within 60 days, $1M within 180 days).
-
Avenue Therapeutics closes $3.25M equity raise; existing warrants repriced to $1.55
Raised ~$3.25M gross via registered direct offering of 1,940,299 shares and pre-funded warrants, plus private placement of 1,940,299 warrants.
-
Q3 2022 net loss $0.7M ($0.45/share) vs $0.9M ($0.79/share) in Q3 2021.
-
Avenue Therapeutics completes acquisition of Baergic Bio and its CNS asset BAER-101
Acquired majority of Baergic Bio shares from Fortress Biotech; Baergic now a subsidiary of Avenue.
-
On Oct 18, 2022, Nasdaq confirmed Avenue Therapeutics met the $1.00 bid price and $2.5M stockholders' equity requirements for continued listing.
-
Avenue Therapeutics closes $12M offering, net $10.4M; uses proceeds to repurchase InvaGen shares
Closed underwritten offering of 3,636,365 units at $3.30/unit; net proceeds ~$10.4M.
-
Nasdaq Hearings Panel granted continued listing through Oct 31, 2022 to demonstrate compliance with stockholders' equity minimum of $2.5M.
Executive changes
Appointed
Alexandra MacLean
Director
ATXI ·
AVENUE THERAPEUTICS, INC.
appointed Alexandra MacLean, M.D., Chief Executive Officer of the Company, to the Board as a director, effective immediately
Departed
Jaideep Gogtay, M.D.
Director
ATXI ·
AVENUE THERAPEUTICS, INC.
each of Jaideep Gogtay, M.D. and E. Garrett Ingram, the two non-independent members of the Board originally selected by InvaGen, resigned as members of the Board and all committees thereof, effective immediately.
Departed
E. Garrett Ingram
Director
ATXI ·
AVENUE THERAPEUTICS, INC.
each of Jaideep Gogtay, M.D. and E. Garrett Ingram, the two non-independent members of the Board originally selected by InvaGen, resigned as members of the Board and all committees thereof, effective immediately.
Role change
(interim)
David Jin
Interim Chief Executive Officer
ATXI ·
AVENUE THERAPEUTICS, INC.
With the appointment of Dr. MacLean as the new Chief Executive Officer, Mr. David Jin will end his term as interim Chief Executive Officer and will continue his responsibilities as Interim Chief Financial Officer and Chief Operating Officer of the Company.
Appointed
Alexandra MacLean, M.D.
Chief Executive Officer
ATXI ·
AVENUE THERAPEUTICS, INC.
On August 1, 2022, the Board of Directors of Avenue Therapeutics, Inc. (the “ Company ”) appointed Alexandra MacLean, M.D., to serve as the Company’s Chief Executive Officer, with immediate effect.
Appointed
Faith L. Charles
director
ATXI ·
AVENUE THERAPEUTICS, INC.
On May 16, 2022, the Board appointed Faith L. Charles as a director
Appointed
(interim)
David Jin
Interim Principal Financial Officer
ATXI ·
AVENUE THERAPEUTICS, INC.
On May 11, 2022, Avenue Therapeutics, Inc. (the “Company”) appointed David Jin as the Company’s Interim Principal Financial Officer.
Role change
(interim)
David Jin
interim principal executive officer
ATXI ·
AVENUE THERAPEUTICS, INC.
David Jin, who was previously serving as the Company’s Chief Operating Officer, will begin acting as the Company’s interim principal executive officer as of March 31, 2022.
Departed
Lucy Lu
President and Chief Executive Officer
ATXI ·
AVENUE THERAPEUTICS, INC.
Lucy Lu, M.D. notified Avenue Therapeutics, Inc. (the “Company”) that she was resigning from her role as the Company’s President and Chief Executive Officer, and from her position as a member of the Company’s Board of Directors, effective in each case as of March 31, 2022
Departed
Joseph Vazzano
Chief Financial Officer
ATXI ·
AVENUE THERAPEUTICS, INC.
Mr. Joseph Vazzano notified Avenue Therapeutics, Inc. (the “Company”) that he was resigning from his role as the Company’s Chief Financial Officer, effective January 14, 2022, to pursue other opportunities.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event other_material